Characterization of New Founder Alu-Mediated Rearrangements in MSH2 Gene Associated with a Lynch Syndrome Phenotype
Por:
Perez-Cabornero, L, Flores, EB, Sanz, MI, Sampedro, EV, Becares, AA, Aras, EL, Gonzalez, JC, Riu, MP, Asensio, TRYC, Munar, GC, Pino, CM, Dominguez, MD
Publicada:
1 oct 2011
Resumen:
It has been reported that large genomic deletions in the MLH1 and MSH2 genes are a frequent cause of Lynch syndrome in certain populations. Here, a cohort has been screened and two new founder rearrangements have been found in the MSH2 gene. These mutations have been characterized by break point determination, haplotype analysis, and genotype-phenotype correlation. Mutations have been identified in the MLH1, MSH2, and MSH6 genes in 303 subjects from 160 suspected Lynch syndrome unrelated families. All subjects were tested using heteroduplex analysis by capillary array electrophoresis. Multiplex ligation-dependent probe amplification was used to detect rearrangements in mutation-negative index patients and confirmed by reverse transcriptase PCR. The break point of the deletions was further characterized by the array comparative genomic hybridization method. Immunohistochemical staining and microsatellite instability were studied in tumor samples. Hereditary nonpolyposis colorectal cancer-related phenotypes were evaluated. More than 16% (24 of 160) of the families had pathogenic mutations (8 MLH1, 15 MSH2, and 1 MSH6). Twelve of these families (50%) are carriers of a novel mutation. Seven of the 15 positive MSH2 families (47%) are carriers of a rearrangement. The exon 7 deletion and exon 4 to 8 deletion of MSH2 are new founder mutations. The segregation of a common haplotype, a similar phenotype, and anticipation effects were observed in these families. These findings will greatly simplify the diagnosis, counseling, and clinical care in suspected Lynch syndrome families and not just in specific geographic areas, so wide distribution may be explained by migration patterns. Cancer Prev Res; 4(10); 1546-55. (C) 2011 AACR.
Filiaciones:
Perez-Cabornero, L:
Univ Valladolid, Canc Genet Lab, IBGM CSIC, Valladolid 47003, Spain
Flores, EB:
ICO IDIBELL, Hereditary Canc Program, Lhospitalet De Llobregat, Spain
Sanz, MI:
Univ Valladolid, Canc Genet Lab, IBGM CSIC, Valladolid 47003, Spain
Sampedro, EV:
Univ Valladolid, Canc Genet Lab, IBGM CSIC, Valladolid 47003, Spain
Becares, AA:
Univ Valladolid, Canc Genet Lab, IBGM CSIC, Valladolid 47003, Spain
Aras, EL:
Hosp Gen Yague, Dept Oncol, Burgos, Spain
Gonzalez, JC:
Hosp Comarcal Medina Campo, Dept Anat Pathol, Valladolid, Spain
Riu, MP:
ICO IDIBELL, Hereditary Canc Program, Lhospitalet De Llobregat, Spain
Asensio, TRYC:
Hosp Santa Creu & Sant Pau, Dept Oncol, Barcelona, Spain
Munar, GC:
ICO IDIBELL, Hereditary Canc Program, Lhospitalet De Llobregat, Spain
Pino, CM:
Univ Valladolid, Canc Genet Lab, IBGM CSIC, Valladolid 47003, Spain
Dominguez, MD:
Univ Valladolid, Canc Genet Lab, IBGM CSIC, Valladolid 47003, Spain
Bronze
|